Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.79 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | RGS12 | O14924 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14446497 | 0.91 | LMNA (0.80) | LMNACYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL14446495 | 0.90 | LMNA (0.89) | LMNACYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL1320560 | 0.88 | LMNA (1.00) | LMNACYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL13802269 | 0.87 | PTGDR2 (0.61) | LMNACYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL13802268 | 0.87 | PTGDR2 (0.61) | LMNACYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL1322507 | 0.87 | LMNA (1.00) | LMNACYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL7963016 | 0.87 | PLA2G2A (1.00) | LMNACYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL13802266 | 0.86 | PTGDR2 (0.60) | LMNACYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL8607505 | 0.86 | PTGS2 (1.00) | LMNACYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL8876121 | 0.84 | LMNA (0.78) | LMNACYP1A2CYP3A4CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | LMNA 394/4885CYP1A2 461/4885CYP3A4 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.